Biotechnology company and drug-delivery platform
innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)has
developed and out-licenses its pioneering-drug delivery platform
DehydraTECH(TM), which improves the speed, taste and delivery of bioactive
compounds, including nicotine and cannabinoids. A recent article discussing the
company reads, “Furthermore, the DehydraTECH drug delivery platform increases
bio-absorption by up to 10 times and lessens the time of onset, with effects
being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without
the platform. In addition, the technology is patent protected for cannabidiol
(CBD) and all other nonpsychoactive cannabinoids. Patents are also granted for
THC (tetrahydrocannabinol), other psychoactive compounds and NSAIDs
(nonsteroidal, anti-inflammatory drugs), as well as nicotine and other
molecules. . . . Lexaria Bioscience has partnered with one of the world’s
largest tobacco companies to fund the research and development of the
DehydraTECH technology for oral nicotine. Through wholly owned subsidiary Lexaria
Nicotine LLC, Lexaria is working to propel innovation in oral, reduced-risk
nicotine consumer products utilizing DehydraTECH (http://ibn.fm/1JjdR).”
To view the full article, visit http://ibn.fm/smpO8
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology, which promotes healthier ingestion methods,
lower overall dosing and higher effectiveness of lipophilic active molecules.
Lexaria has multiple patents pending in over 40 countries around the world and
has patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
